Worg Pharmaceuticals

Worg is a clinical-stage biopharmaceutical company focused on providing breakthrough immunotherapy solutions to effectively combat allergies, autoimmune diseases, and other serious unmet medical needs. The management team of Worg consists of members from China, the United States, and Europe, who possess extensive experience across the entire business chain of the life sciences and healthcare industries, including corporate management, CMC, drug development, regulatory affairs, and product commercialization. The core members of the company have been educated at prestigious universities and have accumulated industry experience from renowned companies and research institutions such as Roche, Johnson & Johnson, Alexion, Shire, the U.S. FDA, Aventis, GlaxoSmithKline, Porton, and Fosun. Established in 2018, Worg is headquartered in Hangzhou, an emerging biotechnology hub in China, with an operational center in Basel, a core region of the European pharmaceutical industry. The company is rapidly expanding its global operations and striving to become a fully integrated pharmaceutical company. Through flexible business models including internal development and external collaboration, Worg is quickly building a pipeline for allergy and autoimmune disease indications based on its two key technology platforms, PCFiT and Apitope. Additionally, the company is actively advancing the development of its proprietary platform for molecular allergy diagnostics. Worg is committed to becoming a world-leading immunotherapy company, providing innovative, safe, and effective treatment options for patients.